<p>Grant Private Wealth Management Inc 在第二季度购买了 Gilead Sciences, Inc. (NASDAQ:GILD - 免费报告) 的新股份，根据其最近向证券交易委员会提交的 13F 文件。这家机构投资者购买了 14,287 股生物制药公司的股票，价值约为 1,584,000 美元。</p>
<p>获取 <strong>Gilead Sciences</strong> 警报：</p>
<ul>
<li>生物技术行业可能在年底前转变为市场领导者</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也对该公司的持仓进行了调整。Farther Finance Advisors LLC 在第二季度将其在 Gilead Sciences 的持股增加了 11.3%。Farther Finance Advisors LLC 目前拥有 41,710 股生物制药公司的股票，价值 4,624,000 美元，此前在上个季度又购买了 4,223 股。Silver Oak Securities Incorporated 在第二季度购买了 Gilead Sciences 的新头寸，价值约为 415,000 美元。CX Institutional 在第二季度将其在 Gilead Sciences 的股份增加了 2.7%。CX Institutional 目前拥有 70,493 股生物制药公司的股票，价值 7,816,000 美元，此前在上个季度又购买了 1,846 股。Wright Investors Service Inc. 在第二季度将其在 Gilead Sciences 的持仓增加了 0.6%。Wright Investors Service Inc. 目前拥有 50,947 股生物制药公司的股票，价值 5,648,000 美元，此前在此期间又购买了 282 股。最后，My Legacy Advisors LLC 在第二季度购买了 Gilead Sciences 的新头寸，价值约为 360,000 美元。对冲基金和其他机构投资者持有该公司 83.67% 的股票。</p>
<h2>内部人士下注</h2>
<p>在相关消息中，首席执行官 Daniel Patrick O'day 于 8 月 28 日星期四出售了 10,000 股该股票。股票以平均价格 113.63 美元出售，总价值为 1,136,300.00 美元。交易后，首席执行官持有该公司 595,725 股股票，价值约为 67,692,231.75 美元。这代表了他们持股比例的 1.65% 的减少。该交易在向 SEC 提交的文件中披露，可以通过此链接访问。此外，内部人士 Johanna Mercier 于 8 月 15 日星期五出售了 28,000 股该股票。股票以平均价格 118.53 美元出售，总价值为 3,318,840.00 美元。完成销售后，内部人士直接持有该公司 114,168 股股票，价值约为 13,532,333.04 美元。该交易使其持仓减少了 19.70%。该销售的披露可以在这里找到。在上个季度，内部人士出售了价值 9,390,030 美元的 82,000 股公司股票。内部人士持有该公司 0.27% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>3 家生物技术巨头受益于美国销售和政策变化</li>
</ul>
<p>一些券商最近对 GILD 发表了评论。Dbs Bank 在 9 月 5 日星期五的研究报告中将 Gilead Sciences 的评级上调至 “适度买入”。Truist Financial 将 Gilead Sciences 的评级从 “持有” 上调至 “买入”，并在 8 月 8 日星期五的报告中将该公司的目标价从 108.00 美元上调至 127.00 美元。加拿大皇家银行在 8 月 8 日星期五的研究报告中将 Gilead Sciences 的目标价从 96.00 美元上调至 98.00 美元，并给予该公司 “行业表现” 评级。大和资本市场在 8 月 19 日星期二的研究报告中将 Gilead Sciences 的评级从 “中性” 上调至 “跑赢大盘”，并设定了 128.00 美元的目标价。最后，Rothschild &amp; Co Redburn 在 9 月 12 日星期五的研究报告中将 Gilead Sciences 的目标价从 136.00 美元上调至 143.00 美元，并给予该公司 “买入” 评级。三位投资分析师对该股票给予了强烈买入评级，十九位给予了买入评级，六位给予了持有评级。根据 MarketBeat，Gilead Sciences 的共识评级为 “适度买入”，共识目标价为 117.17 美元。</p>
<p><strong>获取我们最新的 Gilead Sciences 股票分析</strong></p>
<h2>Gilead Sciences 股票上涨 0.4%</h2>
<ul>
<li>2 只医疗保健股票值得关注，因为摩根大通提升了 Gilead 的评级</li>
</ul>
<p>Gilead Sciences 股票在星期五开盘价为 114.09 美元。该公司的流动比率为 1.32，速动比率为 1.15，债务与股本比率为 1.13。Gilead Sciences, Inc. 的 1 年低点为 81.83 美元，1 年高点为 121.83 美元。该公司的 50 日简单移动平均为 114.10 美元，200 日简单移动平均为 110.03 美元。该公司的市值为 1415.6 亿美元，市盈率为 22.73，市盈增长比率为 0.77，贝塔系数为 0.36。</p>
<p>Gilead Sciences (NASDAQ:GILD - 获取免费报告) 最近于 8 月 7 日星期四发布了季度财报。这家生物制药公司报告本季度每股收益为 2.01 美元，超出市场共识预期的 1.96 美元，超出 0.05 美元。Gilead Sciences 的净利润率为 21.86%，股本回报率为 50.99%。该公司本季度的收入为 70.8 亿美元，而市场共识预期为 69.5 亿美元。在去年同期，该公司每股收益为 2.01 美元。该公司的季度收入同比增长 1.4%。Gilead Sciences 已设定其 2025 财年的指导目标为每股收益 7.950-8.250 美元。分析师预测 Gilead Sciences, Inc. 今年的每股收益将为 7.95 美元。</p>
<h2>Gilead Sciences 分红公告</h2>
<p>该公司还最近宣布了季度分红，将于 9 月 29 日星期一支付。9 月 15 日星期一的股东将获得每股 0.79 美元的分红。这代表了每年 3.16 美元的分红和 2.8% 的分红收益率。除息日为 9 月 15 日星期一。Gilead Sciences 的分红支付比率为 62.95%。</p>
<h2>Gilead Sciences 公司简介</h2>
<p>(免费报告)</p>
<p>吉利德科学公司是一家生物制药公司，在美国、欧洲及国际上发现、开发和商业化满足医疗需求的药物。该公司提供 Biktarvy、Genvoya、Descovy、Odefsey、Truvada、Complera/Eviplera、Stribild、Sunlencs 和 Atripla 等产品用于治疗 HIV/AIDS；Veklury，一种静脉注射药物，用于治疗 COVID-19；以及 Epclusa、Harvoni、Vemlidy 和 Viread 用于治疗病毒性肝炎。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比吉利德科学更好的股票</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>卡特彼勒股票创下历史新高——还有上涨空间吗？</li>
<li>消费品股票解析</li>
<li>伯克希尔支持的 Lennar 在第三季度财报疲软后下滑</li>
<li>哪些华尔街分析师最准确？</li>
<li>分析师对好时的看法转为乐观——百事可乐是下一个价值投资吗？</li>
</ul>
<p><strong>想看看其他对 GILD 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取吉利德科学公司（NASDAQ:GILD - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在吉利德科学吗？</h2>
<p>在考虑吉利德科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而吉利德科学并不在名单上。</p>
<p>虽然吉利德科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

吉利德科学

<p>Grant Private Wealth Management Inc 收购了吉利德科学（Gilead Sciences）价值 158 万美元的股份，在第二季度购买了 14,287 股。其他机构投资者也调整了他们的持仓，其中 Farther Finance Advisors 和 CX Institutional 的增持尤为显著。内部人士出售了大量股份，包括首席执行官 Daniel O'Day 和 Johanna Mercier。分析师们已上调了吉利德的评级，普遍目标价为 117.17 美元。吉利德的股票开盘价为 114.09 美元，上涨了 0.4%，市值为 1415.6 亿美元</p>

<p>Grant Private Wealth Management Inc bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,287 shares of the biopharmaceutical company's stock, valued at approximately $1,584,000.</p>
<div class="lb-trans"><p>Grant Private Wealth Management Inc 在第二季度购买了 Gilead Sciences, Inc. (NASDAQ:GILD - 免费报告) 的新股份，根据其最近向证券交易委员会提交的 13F 文件。这家机构投资者购买了 14,287 股生物制药公司的股票，价值约为 1,584,000 美元。</p>
</div><p>Get <strong>Gilead Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Gilead Sciences</strong> 警报：</p>
</div><ul>
<li>Biotech Sector May Flip to Market Leader by Year-End</li>
</ul>
<div class="lb-trans"><ul>
<li>生物技术行业可能在年底前转变为市场领导者</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Farther Finance Advisors LLC raised its holdings in Gilead Sciences by 11.3% during the second quarter. Farther Finance Advisors LLC now owns 41,710 shares of the biopharmaceutical company's stock worth $4,624,000 after purchasing an additional 4,223 shares in the last quarter. Silver Oak Securities Incorporated bought a new position in Gilead Sciences during the second quarter valued at about $415,000. CX Institutional grew its stake in shares of Gilead Sciences by 2.7% during the second quarter. CX Institutional now owns 70,493 shares of the biopharmaceutical company's stock valued at $7,816,000 after purchasing an additional 1,846 shares during the last quarter. Wright Investors Service Inc. grew its position in shares of Gilead Sciences by 0.6% in the 2nd quarter. Wright Investors Service Inc. now owns 50,947 shares of the biopharmaceutical company's stock valued at $5,648,000 after purchasing an additional 282 shares during the period. Finally, My Legacy Advisors LLC bought a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $360,000. Hedge funds and other institutional investors own 83.67% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也对该公司的持仓进行了调整。Farther Finance Advisors LLC 在第二季度将其在 Gilead Sciences 的持股增加了 11.3%。Farther Finance Advisors LLC 目前拥有 41,710 股生物制药公司的股票，价值 4,624,000 美元，此前在上个季度又购买了 4,223 股。Silver Oak Securities Incorporated 在第二季度购买了 Gilead Sciences 的新头寸，价值约为 415,000 美元。CX Institutional 在第二季度将其在 Gilead Sciences 的股份增加了 2.7%。CX Institutional 目前拥有 70,493 股生物制药公司的股票，价值 7,816,000 美元，此前在上个季度又购买了 1,846 股。Wright Investors Service Inc. 在第二季度将其在 Gilead Sciences 的持仓增加了 0.6%。Wright Investors Service Inc. 目前拥有 50,947 股生物制药公司的股票，价值 5,648,000 美元，此前在此期间又购买了 282 股。最后，My Legacy Advisors LLC 在第二季度购买了 Gilead Sciences 的新头寸，价值约为 360,000 美元。对冲基金和其他机构投资者持有该公司 83.67% 的股票。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In related news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares in the company, valued at approximately $67,692,231.75. This represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares of the company's stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,000 shares of company stock worth $9,390,030. Insiders own 0.27% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Daniel Patrick O'day 于 8 月 28 日星期四出售了 10,000 股该股票。股票以平均价格 113.63 美元出售，总价值为 1,136,300.00 美元。交易后，首席执行官持有该公司 595,725 股股票，价值约为 67,692,231.75 美元。这代表了他们持股比例的 1.65% 的减少。该交易在向 SEC 提交的文件中披露，可以通过此链接访问。此外，内部人士 Johanna Mercier 于 8 月 15 日星期五出售了 28,000 股该股票。股票以平均价格 118.53 美元出售，总价值为 3,318,840.00 美元。完成销售后，内部人士直接持有该公司 114,168 股股票，价值约为 13,532,333.04 美元。该交易使其持仓减少了 19.70%。该销售的披露可以在这里找到。在上个季度，内部人士出售了价值 9,390,030 美元的 82,000 股公司股票。内部人士持有该公司 0.27% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物技术巨头受益于美国销售和政策变化</li>
</ul>
</div><p>A number of brokerages have recently commented on GILD. Dbs Bank raised Gilead Sciences to a &#34;moderate buy&#34; rating in a research report on Friday, September 5th. Truist Financial upgraded Gilead Sciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating and lifted their price target for the company from $108.00 to $127.00 in a report on Friday, August 8th. Royal Bank Of Canada increased their price objective on Gilead Sciences from $96.00 to $98.00 and gave the company a &#34;sector perform&#34; rating in a research note on Friday, August 8th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and set a $128.00 price target on the stock in a research note on Tuesday, August 19th. Finally, Rothschild &amp; Co Redburn upped their price objective on Gilead Sciences from $136.00 to $143.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, September 12th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Gilead Sciences has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $117.17.</p>
<div class="lb-trans"><p>一些券商最近对 GILD 发表了评论。Dbs Bank 在 9 月 5 日星期五的研究报告中将 Gilead Sciences 的评级上调至 “适度买入”。Truist Financial 将 Gilead Sciences 的评级从 “持有” 上调至 “买入”，并在 8 月 8 日星期五的报告中将该公司的目标价从 108.00 美元上调至 127.00 美元。加拿大皇家银行在 8 月 8 日星期五的研究报告中将 Gilead Sciences 的目标价从 96.00 美元上调至 98.00 美元，并给予该公司 “行业表现” 评级。大和资本市场在 8 月 19 日星期二的研究报告中将 Gilead Sciences 的评级从 “中性” 上调至 “跑赢大盘”，并设定了 128.00 美元的目标价。最后，Rothschild &amp; Co Redburn 在 9 月 12 日星期五的研究报告中将 Gilead Sciences 的目标价从 136.00 美元上调至 143.00 美元，并给予该公司 “买入” 评级。三位投资分析师对该股票给予了强烈买入评级，十九位给予了买入评级，六位给予了持有评级。根据 MarketBeat，Gilead Sciences 的共识评级为 “适度买入”，共识目标价为 117.17 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Gilead Sciences</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 Gilead Sciences 股票分析</strong></p>
</div><h2>Gilead Sciences Stock Up 0.4%</h2>
<div class="lb-trans"><h2>Gilead Sciences 股票上涨 0.4%</h2>
</div><ul>
<li>2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只医疗保健股票值得关注，因为摩根大通提升了 Gilead 的评级</li>
</ul>
</div><p>Gilead Sciences stock opened at $114.09 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 1-year low of $81.83 and a 1-year high of $121.83. The firm has a 50 day simple moving average of $114.10 and a 200 day simple moving average of $110.03. The firm has a market capitalization of $141.56 billion, a price-to-earnings ratio of 22.73, a P/E/G ratio of 0.77 and a beta of 0.36.</p>
<div class="lb-trans"><p>Gilead Sciences 股票在星期五开盘价为 114.09 美元。该公司的流动比率为 1.32，速动比率为 1.15，债务与股本比率为 1.13。Gilead Sciences, Inc. 的 1 年低点为 81.83 美元，1 年高点为 121.83 美元。该公司的 50 日简单移动平均为 114.10 美元，200 日简单移动平均为 110.03 美元。该公司的市值为 1415.6 亿美元，市盈率为 22.73，市盈增长比率为 0.77，贝塔系数为 0.36。</p>
</div><p>Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter in the previous year, the firm earned $2.01 earnings per share. The company's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.</p>
<div class="lb-trans"><p>Gilead Sciences (NASDAQ:GILD - 获取免费报告) 最近于 8 月 7 日星期四发布了季度财报。这家生物制药公司报告本季度每股收益为 2.01 美元，超出市场共识预期的 1.96 美元，超出 0.05 美元。Gilead Sciences 的净利润率为 21.86%，股本回报率为 50.99%。该公司本季度的收入为 70.8 亿美元，而市场共识预期为 69.5 亿美元。在去年同期，该公司每股收益为 2.01 美元。该公司的季度收入同比增长 1.4%。Gilead Sciences 已设定其 2025 财年的指导目标为每股收益 7.950-8.250 美元。分析师预测 Gilead Sciences, Inc. 今年的每股收益将为 7.95 美元。</p>
</div><h2>Gilead Sciences Dividend Announcement</h2>
<div class="lb-trans"><h2>Gilead Sciences 分红公告</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio is 62.95%.</p>
<div class="lb-trans"><p>该公司还最近宣布了季度分红，将于 9 月 29 日星期一支付。9 月 15 日星期一的股东将获得每股 0.79 美元的分红。这代表了每年 3.16 美元的分红和 2.8% 的分红收益率。除息日为 9 月 15 日星期一。Gilead Sciences 的分红支付比率为 62.95%。</p>
</div><h2>Gilead Sciences Profile</h2>
<div class="lb-trans"><h2>Gilead Sciences 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.</p>
<div class="lb-trans"><p>吉利德科学公司是一家生物制药公司，在美国、欧洲及国际上发现、开发和商业化满足医疗需求的药物。该公司提供 Biktarvy、Genvoya、Descovy、Odefsey、Truvada、Complera/Eviplera、Stribild、Sunlencs 和 Atripla 等产品用于治疗 HIV/AIDS；Veklury，一种静脉注射药物，用于治疗 COVID-19；以及 Epclusa、Harvoni、Vemlidy 和 Viread 用于治疗病毒性肝炎。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Gilead Sciences</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>Caterpillar Stock Hits All-Time High—Is There More Room to Run?</li>
<li>Consumer Staples Stocks, Explained</li>
<li>Berkshire-Backed Lennar Slides After Weak Q3 Earnings</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Analysts Turn Bullish on Hershey—Is Pepsi the Next Value Play?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比吉利德科学更好的股票</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>卡特彼勒股票创下历史新高——还有上涨空间吗？</li>
<li>消费品股票解析</li>
<li>伯克希尔支持的 Lennar 在第三季度财报疲软后下滑</li>
<li>哪些华尔街分析师最准确？</li>
<li>分析师对好时的看法转为乐观——百事可乐是下一个价值投资吗？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding GILD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 GILD 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取吉利德科学公司（NASDAQ:GILD - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0lMRA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=GILD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Gilead Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在吉利德科学吗？</h2>
</div><p>Before you consider Gilead Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑吉利德科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而吉利德科学并不在名单上。</p>
</div><p>While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然吉利德科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Grant Private Wealth Management Inc 在吉利德科学公司 $GILD 中建立了价值 158 万美元的头寸